We have successful products – including the blockbuster Lidoderm® patch – but our teams are continuing to develop innovative products to address unmet needs in the market. We are known for developing and manufacturing complex formulations entirely in house that are difficult for competitors to replicate.
Teikoku Pharma USA (TPU), a subsidiary of Teikoku Seiyaku, Japan, is a family-owned, privately-held international specialty pharmaceutical company founded in 1997 in California.
We develop innovative products in several therapeutic areas, including pain management, CNS disorders, dermatology, and oncology, using our proprietary and innovative drug delivery platforms, including patches, injectables, gels, creams, and ointments. Our team can take an asset from conception to FDA approval, including R&D, clinical, regulatory, and manufacturing.
Teikoku Seiyaku has a storied history of technological innovation and business success.
Shozo Akazawa, the 5th head of the family, is certified by the government to deal in medicines, and starts the business.
Teikoku Seiyaku is established with 1 million yen in capital in Kagawa Prefecture, Japan.
Horxis launches in Japan, a prototype of the current medicated plaster.
Osaka Plant spins off of Teikoku Seiyaku, and with it, Fuso Chemical Industry Co. Ltd.
Teikoku Seiyaku’s medicated plasters are approved for prescription use, becoming the company’s main product line.
The first stage of the new production plant for plasters is completed. The final stage of construction is completed in 1978.
Teikoku Kampo Seiyaku Co. Ltd, Teikoku’s subsidiary company that specializes in herbal medicine, is established.
Catlep, Japan’s first transdermal indomethacin plaster for prescription use, is approved and production begins.
Seltouch, a transdermal felbinac plaster for prescription use, is approved and production begins.
Non-prescription drug division (OTC) spins off as an independent company, Teikoku Pharmacare, Co. Ltd.
Teikoku Pharma USA is established.
FDA grants approval for Lidoderm in the US.
Fuso Teiyaku is established in Qingdao, China.
Versatis receives MHRA approval in UK, and Flector receives FDA approval in the US.
TPU acquires Travanti Pharma.
FDA grants approval for Docetaxel Non-Alcohol Formula in the US.
